메뉴 건너뛰기
Journal of Diabetes
Volumn 8, Issue 3, 2016, Pages 300-304
Diabetes News
Author keywords

[No Author keywords available]
Indexed keywords

FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SITAGLIPTIN;
EID: 84964077847     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12377     Document Type: Note
Times cited : (36)
References (8)
  • 1
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
    • (2008) N Engl J Med , vol.358 , pp. 2545-2559
  • 2
    • 77954654472 scopus 로고    scopus 로고
    • Effects of medical therapies on retinopathy progression in type 2 diabetes
    • The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244.
    • (2010) N Engl J Med , vol.363 , pp. 233-244
  • 3
    • 80054748660 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): A randomised open-label substudy
    • Launer L, Miller M, Williamson J, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): A randomised open-label substudy. Lancet Neurol. 2011; 10: 969-77.
    • (2011) Lancet Neurol , vol.10 , pp. 969-977
    • Launer, L.1    Miller, M.2    Williamson, J.3
  • 4
    • 84937053742 scopus 로고    scopus 로고
    • Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
    • Green B, Bethel A, Armstrong P, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232-42.
    • (2015) N Engl J Med , vol.373 , pp. 232-242
    • Green, B.1    Bethel, A.2    Armstrong, P.3
  • 5
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • Scirica B, Bhatt D, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-26.
    • (2013) N Engl J Med , vol.369 , pp. 1317-1326
    • Scirica, B.1    Bhatt, D.2    Braunwald, E.3
  • 6
    • 84883745765 scopus 로고    scopus 로고
    • Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    • White W, Cannon C, Heller S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327-35.
    • (2013) N Engl J Med , vol.369 , pp. 1327-1335
    • White, W.1    Cannon, C.2    Heller, S.3
  • 7
    • 84962129833 scopus 로고    scopus 로고
    • Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes mellitus previously treated with basal insulin: IMAGINE 5
    • Buse J, Rodbard H, Serrano C, et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes mellitus previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016; 39: 92-100.
    • (2016) Diabetes Care , vol.39 , pp. 92-100
    • Buse, J.1    Rodbard, H.2    Serrano, C.3
  • 8
    • 84923686666 scopus 로고    scopus 로고
    • Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway
    • Wang M, Yan H, Shi Z, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci USA. 2015; 112: 2503-8.
    • (2015) Proc Natl Acad Sci USA , vol.112 , pp. 2503-2508
    • Wang, M.1    Yan, H.2    Shi, Z.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.